ArticleMaterials today. Bio2025
A pathogen peptidoglycan scaffold coated with artificial biomembrane promotes broad resistance to bacterial infections by dynamically reprogramming macrophage metabolism.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment.Drug delivery and translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing severity of multidrug-resistant (MDR) bacteria and the shortage of effective treatment strategies urgently require the development of new immunotherapies to combat superbug infections. Trained immunity may offer a novel and effective mechanism to combat resistant superbugs. However, there are currently few materials capable of effectively activating trained immunity, highlighting the need for new agents that provide more durable protection. In this study, we developed a bacterium-like particle (BLP) based on protein-free artificial biomembrane coating immune activator, named LM@pBLP, which features a simple and rapid preparation process, excellent biocompatibility, long-term stability, and a cost-effective advantage. LM@pBLP trains the immune system to target a broad range of pathogens, offering rapid, broad-spectrum, and long-lasting protection against MDR infections. After stimulation with LM@pBLP, it activates glutathione metabolism and amino acid metabolism, induces macrophage metabolic and epigenetic reprogramming changes, and regulates phagocytosis and inflammatory responses to infection. Additionally, LM@pBLP regulates reactive oxygen species (ROS), thereby maintaining oxidative stress homeostasis. Our study demonstrates that LM@pBLP primarily provides rapid, broad-spectrum, and long-lasting protection for experimental animals by activating trained immunity, which opens a new avenue for addressing MDR infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.